Cargando...
JAK2 inhibitors for myeloproliferative neoplasms: what is next?
Since its approval in 2011, the Janus kinase 1/2 (JAK1/2) inhibitor ruxolitinib has evolved to become the centerpiece of therapy for myelofibrosis (MF), and its use in patients with hydroxyurea resistant or intolerant polycythemia vera (PV) is steadily increasing. Several other JAK2 inhibitors have...
Guardado en:
| Publicado en: | Blood |
|---|---|
| Autores principales: | , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
American Society of Hematology
2017
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5510786/ https://ncbi.nlm.nih.gov/pubmed/28500170 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2017-04-742288 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|